| Literature DB >> 36033433 |
Chenan Xu1, Yuanyuan Peng2, Weifang Zhu2, Zhongyue Chen2, Jianrui Li3, Wenhao Tan2, Zhiqiang Zhang3,4, Xinjian Chen1,2.
Abstract
Objectives: To develop and validate an efficient and automatically computational approach for stratifying glioma grades and predicting survival of lower-grade glioma (LGG) patients using an integration of state-of-the-art convolutional neural network (CNN) and radiomics. Method: This retrospective study reviewed 470 preoperative MR images of glioma from BraTs public dataset (n=269) and Jinling hospital (n=201). A fully automated pipeline incorporating tumor segmentation and grading was developed, which can avoid variability and subjectivity of manual segmentations. First, an integrated approach by fusing CNN features and radiomics features was employed to stratify glioma grades. Then, a deep-radiomics signature based on the integrated approach for predicting survival of LGG patients was developed and subsequently validated in an independent cohort.Entities:
Keywords: automatic diagnosis; convolutional neural network; glioma grade; radiomics; survival of lower-grade glioma
Year: 2022 PMID: 36033433 PMCID: PMC9413530 DOI: 10.3389/fonc.2022.969907
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 5.738
Figure 1Workflow of automatic tumor grading. Resnet18 was used to extract CNN features, and SVM was selected as the classifier.
Figure 2Workflow of developing deep-radiomics signature, the regression network was guided by the classification network. Elastic Net was used to develop the deep radiomics signature.
The experimental results of tumor grading using combination of CNN and radiomics methods.
| Methods | AUC (95% CI) | Accuracy | Sensitivity | Precision |
|---|---|---|---|---|
| Baseline (MRI patches) | 0.945 (0.938, 0.952) | 0.922 | 0.923 | 0.962 |
| Baseline + SE module (MRI patches) | 0.958 (0.955,0.961) | 0.941 | 0.971 | 0.931 |
| Baseline (complete MRI) | 0.904 (0.898, 0.910) | 0.871 | 0.912 | 0.891 |
| Baseline + SE module (complete MRI) | 0.932 (0.928, 0.936) | 0.881 | 0.901 | 0.872 |
The experimental results of grading using CNN methods.
| CNN methods | AUC (95% CI) | Accuracy | Sensitivity | Precision |
|---|---|---|---|---|
| Baseline (MRI patches) | 0.846 (0.839, 0.855) | 0.868 | 0.912 | 0.860 |
| Baseline + SE module (MRI patches) | 0.852 (0.846,0.858) | 0.874 | 0.931 | 0.841 |
| Baseline (complete MRI) | 0.801 (0.794, 0.811) | 0.822 | 0.873 | 0.797 |
| Baseline + SE module (complete MRI) | 0.794 (0.786, 0.802) | 0.833 | 0.908 | 0.804 |
Figure 3Kaplan-Meier plot for OS of patients stratified by the median value of deep-radiomics signature. Significantly favorable survival in low-risk patients compared to high-risk patients was shown in the training cohort (A) and the validation cohort (B). Use of the developed integrated nomogram (C) and clinical nomogram (D) estimated the OS for LGG.
Multivariate Cox regression analyses for overall survival in the training and validation cohorts of patients with LGG.
| Characteristics | Training cohort | Validation cohort | ||
|---|---|---|---|---|
| HR (95% CI) |
| HR (95% CI) |
| |
| Age | 1.03 (1.01-1.06) | 0.003 | 1.08 (1.03-1.14) | 0.003 |
| Grade III vs. II; | 1.96 (1.49-2.43) | 0.188 | 3.77 (0.88 -6.66) | 0.073 |
| Histologic type, O vs. A | 0.31 (0.06-0.56) | <0.001 | 0.17 (0.04-0.30) | 0.020 |
| Histologic type, OA vs. A | 2.27 (0.97-3.57) | 0.060 | 1.44 (0.23-2.65) | 0.699 |
| Contrast enhancement vs. not enhanced | 1.55 (0.86-2.24) | 0.140 | 3.65 (1.85-5.45) | 0.059 |
| Signature above the median vs. below the median | 5.69 (4.39-6.99) | <0.001 | 6.28 (4.32-8.23) | <0.001 |
HR, Hazard Ratio; 95% CI, 95% Confidence Interval; O, Oligodendroglioma; A, Astrocytoma; OA, Oligoastrocytoma; Signature, Deep- radiomics signature.
Multivariate Cox regression analyses of clinical data for overall survival in the training and validation cohorts of patients with LGG.
| Characteristic | Training cohort | Validation cohort | ||
|---|---|---|---|---|
| HR (95% CI) |
| HR (95% CI) |
| |
| Age | 1.04 (1.02-1.06) | <0.001 | 1.08 (1.03-1.14) | 0.003 |
| Grade III vs. II; | 1.85 (1.49-2.21) | 0.026 | 5.26 (1.95-8.57) | 0.009 |
| Histologic type, O vs. A | 0.35 (0.19-0.51) | <0.001 | 0.17 (0.04-0.30) | 0.011 |
| Histologic type, OA vs. A | 2.22 (0.97-3.47) | 0.059 | 2.38 (1.40-3.36) | 0.017 |
| Contrast enhancement vs. Not enhanced | 3.26 (2.59-3.93) | 0.032 | 5.57 (3.21-7.93) | 0.002 |
HR, Hazard Ratio; 95% CI, 95% Confidence Interval; O, Oligodendroglioma; A, Astrocytoma; OA, Oligoastrocytoma.
Figure 4The calibration curves of the integrated nomograms in training cohort (A) and the validation cohort (B), along with the clinical nomograms in training cohort (C) and the validation cohort (D).